Boardman High School senior diagnosed with rare condition
Kayden Beish has FAP, Familial Adenomatous Polyposis, a genetic mutation in genes that would normally protect against the growth of polyps.
'It's really hard to even think about at my age, especially,' Beish said.
Beish is 18. She's had stomach pain for years but was just diagnosed with FAP last year. She has 100 polyps right now in her GI tract.
'I have good days and bad days, so sometimes I'll have a lot of pain and I can't go to school, I can't go to work or hang out with my friends,' she said.
FAP usually leads to colon cancer. It's not pretty to think about but her Mom believes in her.
'If anybody can handle this, it is Kayden. She perseveres and pushes through and overcomes anything that's thrown at her,' said her mother Katie Fuline.
FAP was a giant diagnosis, words the family had never heard. It's even tougher for a girl during her senior year, looking forward to life. Beish will have to think about surgeries and whether it could lead to something worse.
'And that's our goal, is to just keep up with the testing and keep on top of it, and never let this get to cancer. But you never know,' Fuline said.
Beish is going to Hawaii over spring break. The trip is from Make A Wish. 'Kayden's Krew' bracelets also show the support she's getting from her family and at school to keep her spirits up. And later this month, a spaghetti dinner will raise vital support to help her now and in the future — because there's no cure for FAP.
'I never want there to be a time where she says I can't get testing done, or I can't have a surgery done because I don't have the money available for it,' Fuline said.
FAP is something Kayden will keep fighting.
Kayden's Krew Spaghetti Dinner will be March 30 at the Boardman High School cafeteria from 1-5 p.m. Tickets for those 13 and up cost $12, children 5-12 are $8 and kids under four are free.
In addition, there will be basket raffles and a bake sale. You can even donate cookies or cakes to be sold.
To purchase tickets or donate baskets call Marlene at 330-207-6304 or Heidi at 330-984-5735.
Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
23-06-2025
- Yahoo
Biodexa Unveils "Serenta" as the Name of its Upcoming Phase 3 Study In Familial Adenomatous Polyposis (FAP)
June 23, 2025 Biodexa Unveils "Serenta" as the Name of its Upcoming Phase 3 Study In Familial Adenomatous Polyposis (FAP) Biodexa Pharmaceuticals PLC ('Biodexa' or 'the Company'), (Nasdaq: BDRX), a clinical stage biopharmaceutical company developing a pipeline of innovative products for the treatment of diseases with unmet medical needs, is pleased to announce it has selected Serenta as the brand name for its upcoming phase 3 clinical study in familial adenomatous polyposis (FAP). In conjunction with this announcement, the company launched a dedicated website, to provide information and resources for patients, caregivers, and healthcare professionals. Serenta reflects Biodexa's commitment to supporting the FAP community and fostering collaboration with stakeholders. The new website offers details about the study's objectives, background on FAP, and ongoing updates as the program progresses. 'We are pleased to introduce Serenta as the identity for our planned pivotal study of eRapa in FAP,' said Gary Shangold, CMO at Biodexa. 'Our goal is to provide clear, accessible information and to engage with the FAP community as we advance this important work.' For more information, please visit About eRapa eRapa is a proprietary oral tablet formulation of rapamycin, also known as sirolimus. Rapamycin is an mTOR (mammalian Target Of Rapamycin) inhibitor. mTOR has been shown to have a significant role in the signalling pathway that regulates cellular metabolism, growth and proliferation and is activated during tumorgenesis3. Importantly, mTOR has been shown to be over-expressed in FAP polyps – thereby underscoring the rationale for using a potent and safe mTOR inhibitor like eRapa to treat FAP. Rapamycin is approved in the US for organ rejection in renal transplantation as Rapamune®(Pfizer). Through the use of nanotechnology and pH sensitive polymers, eRapa is designed to address the poor bioavailability, variable pharmacokinetics and toxicity generally associated with the currently available forms of rapamycin. eRapa is protected by a number of issued patents which extend through 2035, with other pending applications potentially providing further protection beyond 2035. For more information, please contact: Biodexa Pharmaceuticals PLC Stephen Stamp, CEO, CFO Tel: +44 (0)29 20480 180 About Biodexa Pharmaceuticals PLC Biodexa Pharmaceuticals PLC (listed on NASDAQ: BDRX) is a clinical stage biopharmaceutical company developing a pipeline of innovative products for the treatment of diseases with unmet medical needs. The Company's lead development programs include eRapa, under development for Familial Adenomatous Polyposis and Non-Muscle Invasive Bladder Cancer; tolimidone, under development for the treatment of type 1 diabetes; and MTX110, which is being studied in aggressive rare/orphan brain cancer indications. eRapa is a proprietary oral tablet formulation of rapamycin, also known as sirolimus. Rapamycin is an mTOR (mammalian Target Of Rapamycin) inhibitor. mTOR has been shown to have a significant role in the signalling pathway that regulates cellular metabolism, growth and proliferation and is activated during tumorigenesis. Tolimidone is an orally delivered, potent and selective inhibitor of Lyn kinase. Lyn is a member of the Src family of protein tyrosine kinases, which is mainly expressed in hematopoietic cells, in neural tissues, liver, and adipose tissue. Tolimidone demonstrates glycaemic control via insulin sensitization in animal models of diabetes and has the potential to become a first in class blood glucose modulating agent. MTX110 is a solubilized formulation of the histone deacetylase (HDAC) inhibitor, panobinostat. This proprietary formulation enables delivery of the product via convection-enhanced delivery (CED) at chemotherapeutic doses directly to the site of the tumor, by-passing the blood-brain barrier and potentially avoiding systemic toxicity. Biodexa is supported by three proprietary drug delivery technologies focused on improving the bio-delivery and bio-distribution of medicines. Biodexa's headquarters and R&D facility is in Cardiff, UK. For more information visit Forward-Looking StatementsCertain statements in this announcement may constitute 'forward-looking statements' within the meaning of legislation in the United Kingdom and/or United States. Such statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 and are based on management's belief or interpretation. All statements contained in this announcement that do not relate to matters of historical fact should be considered forward-looking statements. In certain cases, forward-looking statements can be identified by the use of words such as 'plans', 'expects' or 'does not anticipate', or 'believes', or variations of such words and phrases or statements that certain actions, events or results 'may', 'could', 'would', 'might' or 'will be taken', 'occur' or 'be achieved.' Forward-looking statements and information are subject to various known and unknown risks and uncertainties, many of which are beyond the ability of the Company to control or predict, that may cause their actual results, performance or achievements to be materially different from those expressed or implied thereby, and are developed based on assumptions about such risks, uncertainties and other factors set out herein. Reference should be made to those documents that Biodexa shall file from time to time or announcements that may be made by Biodexa in accordance with the rules and regulations promulgated by the SEC, which contain and identify other important factors that could cause actual results to differ materially from those contained in any projections or forward-looking statements. These forward-looking statements speak only as of the date of this announcement. All subsequent written and oral forward-looking statements by or concerning Biodexa are expressly qualified in their entirety by the cautionary statements above. Except as may be required under relevant laws in the United States, Biodexa does not undertake any obligation to publicly update or revise any forward-looking statements because of new information, future events or events otherwise arising.
The Hill
19-06-2025
- The Hill
Children's cough syrup recalled over bacteria concerns
(WKBN) – The presence of a bacterium that can cause two types of foodborne illnesses has prompted the recall of multiple lots of a children's cough syrup, a notice posted to the Food and Drug Administration's website announced this week. Medtech Products Inc. is recalling five lots of Little Remedies Honey Cough Syrup due to the presence of Bacillus cereus, as well as the 'loss of shelf-stability,' the company explained. The recalled products were distributed nationwide. They were sold 4-ounce bottles, both in stores and online, between Dec. 14, 2022, and June 4, 2025. Identifying information, including the UPC and lot numbers, as well as the expiration dates, can be found below: No other Little Remedies products were included in the recall. While no serious adverse events have been reported in connection to the cough syrup, the FDA warns that Bacillus cereus can cause short-term illness and, in some cases, lead to death. Bacillus cereus, or B. cereus, is a spore-forming bacterium that commonly exists in our environment, the Cleveland Clinic explains. Exposure to the toxin it creates can result in one of two types of illness — one described as a diarrheal syndrome and another as a vomiting syndrome. The first is characterized by cramps and watery diarrhea, while the second more commonly causes nausea and vomiting. In severe cases, Bacillus cereus infection can lead to death. Those who believe they may be suffering from an illness caused by Bacillus cereus are urged to contact a healthcare provider. Customers who purchased the recalled Little Remedies cough syrup are being told to discard the product. Those with questions or refund requests can reach Medtech at 1-800-754-8853, by email at medicalaffairs@ or through the company's website.
Yahoo
18-06-2025
- Yahoo
Savannah State University welcomes Make-A-Wish family
SAVANNAH, Ga. (WSAV) — Make-A-Wish Georgia is granting an opportunity of a lifetime, offering hands-on experience with the world beneath the surface for a 12-year-old. Mason Downey was diagnosed with cystic fibrosis at age five, a genetic disorder that primarily affects the lungs and digestive system. His family traveled from Indiana to Savannah to allow Mason the chance to realize a dream. 'I have been using microscopes to explore plankton and other stuff,' Downey said. 'And then I've also been exploring how to identify a dolphin by their sounds.' Thanks to Make-a-Wish, Downey is getting the chance to learn alongside marine biology students. It is a passion fueled by his desire to protect ocean life. 'I really just want to help the ocean because it's slowly dying, and I just really feel bad for it,' he said. Savannah State University's marine biology department stepped in to help Downey learn more about the life of an ocean scientist. They set up several labs for the 12-year-old to observe, each focusing on a different aspect of marine biology. 'We're so delighted to just be part of his journey,' Victoria Young said. The experience has touched not only Downey, but his family as well. His mother, Kristen Downey, left with a full heart. 'Being here at Savannah State [University] is really nice because it's exciting to see him living this dream,' Kristen said. 'Learning about becoming a marine biologist, learning about college in general, so that in a few years he can go to college and this maybe one of his choices. I'm just very excited as a mom to see him get to experience this.' With hands-on practice under his belt, Downey is moving full steam ahead with plans for his future. 'I really want to move down to a coastline and become a marine biologist,' said Mason. Make-A-Wish Georgia grants life-changing wishes for children with critical illnesses. Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
